Skip to main content
. 2024 Feb 12;130(8):1316–1323. doi: 10.1038/s41416-023-02569-4

Fig. 2. BM-PFS.

Fig. 2

No correlation was confirmed between any-site progression free survival from brain metastasis (BM) resection (BM-PFS) and TMB (Tumor Mutation Burden) on BM (a); on the other hand, HER2 amplification (HER2+) (b) and KRAS mutations (c) on BM yielded better BM-PFS. A non-statistically significant advantage in BM-PFS was observed in case of TILS ≥ 1.6 on BM (d).